CL2016002151A1 - Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico - Google Patents

Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico

Info

Publication number
CL2016002151A1
CL2016002151A1 CL2016002151A CL2016002151A CL2016002151A1 CL 2016002151 A1 CL2016002151 A1 CL 2016002151A1 CL 2016002151 A CL2016002151 A CL 2016002151A CL 2016002151 A CL2016002151 A CL 2016002151A CL 2016002151 A1 CL2016002151 A1 CL 2016002151A1
Authority
CL
Chile
Prior art keywords
prevention
treatment
pyridazine derivatives
ataxic disorder
ataxic
Prior art date
Application number
CL2016002151A
Other languages
English (en)
Spanish (es)
Inventor
Sarah Almond
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50554599&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016002151(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of CL2016002151A1 publication Critical patent/CL2016002151A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2016002151A 2014-03-06 2016-08-25 Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico CL2016002151A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1403944.0A GB201403944D0 (en) 2014-03-06 2014-03-06 New use

Publications (1)

Publication Number Publication Date
CL2016002151A1 true CL2016002151A1 (es) 2016-12-30

Family

ID=50554599

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016002151A CL2016002151A1 (es) 2014-03-06 2016-08-25 Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico

Country Status (32)

Country Link
US (1) US20170014407A1 (enExample)
EP (1) EP3113778B1 (enExample)
JP (1) JP6510549B2 (enExample)
KR (1) KR20160126081A (enExample)
CN (1) CN106102743A (enExample)
AU (1) AU2015225954B2 (enExample)
CA (1) CA2940342A1 (enExample)
CL (1) CL2016002151A1 (enExample)
CY (1) CY1120573T1 (enExample)
DK (1) DK3113778T3 (enExample)
EA (1) EA036438B1 (enExample)
ES (1) ES2676905T3 (enExample)
GB (1) GB201403944D0 (enExample)
GE (1) GEP20196984B (enExample)
HR (1) HRP20181082T1 (enExample)
IL (1) IL247435A0 (enExample)
LT (1) LT3113778T (enExample)
MA (1) MA39315A1 (enExample)
MX (1) MX2016010524A (enExample)
MY (1) MY202127A (enExample)
PH (1) PH12016501751A1 (enExample)
PL (1) PL3113778T3 (enExample)
PT (1) PT3113778T (enExample)
RS (1) RS57594B1 (enExample)
SG (1) SG11201607106YA (enExample)
SI (1) SI3113778T1 (enExample)
SM (1) SMT201800367T1 (enExample)
TR (1) TR201809537T4 (enExample)
TW (1) TW201534591A (enExample)
UA (1) UA123352C2 (enExample)
WO (1) WO2015132608A1 (enExample)
ZA (1) ZA201604611B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
GB201222711D0 (en) 2012-12-17 2013-01-30 Takeda Pharmaceutical Novel compounds
US10118917B2 (en) 2014-04-29 2018-11-06 E I Du Pont De Nemours And Company Pyridazinone herbicides
TWI785022B (zh) 2017-03-28 2022-12-01 美商富曼西公司 新穎噠嗪酮類除草劑
US11213030B2 (en) 2017-06-30 2022-01-04 Fmc Corporation 4-(3,4-dihydronaphth-1-yl or 2H-chromen-4-yl)-5-hydroxy-2H-pyradizin-3-ones as herbicides
CN112569217B (zh) * 2019-09-30 2022-04-22 厦门大学 戊酸衍生物在治疗遗传性小脑共济失调中的应用
JP2021138648A (ja) 2020-03-04 2021-09-16 武田薬品工業株式会社 経口固形製剤
CA3209781A1 (en) 2021-03-01 2022-09-09 Takeda Pharmaceuticals Company Limited Use of luvadaxistat for the treatment of cognitive impairment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE321553T1 (de) * 1998-06-10 2006-04-15 Meiji Seika Kaisha Arzneimittel für hinterstrangataxie und zusammensetzung zur behandlung von hinterstrangataxie
WO2003047558A2 (en) * 2001-12-03 2003-06-12 Genset S.A. Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase inhibitors
JO3115B1 (ar) * 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao

Also Published As

Publication number Publication date
CA2940342A1 (en) 2015-09-11
EA036438B1 (ru) 2020-11-11
SMT201800367T1 (it) 2018-09-13
GB201403944D0 (en) 2014-04-23
JP6510549B2 (ja) 2019-05-08
MA39315A1 (fr) 2017-09-29
AU2015225954B2 (en) 2020-06-18
RS57594B1 (sr) 2018-11-30
SG11201607106YA (en) 2016-09-29
TW201534591A (zh) 2015-09-16
PL3113778T3 (pl) 2018-11-30
KR20160126081A (ko) 2016-11-01
DK3113778T3 (en) 2018-07-30
JP2017507156A (ja) 2017-03-16
TR201809537T4 (tr) 2018-07-23
EP3113778B1 (en) 2018-06-06
ES2676905T3 (es) 2018-07-26
LT3113778T (lt) 2018-08-27
AU2015225954A1 (en) 2016-07-07
GEP20196984B (en) 2019-06-25
MX2016010524A (es) 2016-10-31
CN106102743A (zh) 2016-11-09
SI3113778T1 (en) 2018-08-31
EA201691566A1 (ru) 2016-12-30
PH12016501751A1 (en) 2017-02-06
MY202127A (en) 2024-04-05
UA123352C2 (uk) 2021-03-24
IL247435A0 (en) 2016-11-30
PT3113778T (pt) 2018-07-11
WO2015132608A1 (en) 2015-09-11
ZA201604611B (en) 2017-09-27
EP3113778A1 (en) 2017-01-11
CY1120573T1 (el) 2019-07-10
HRP20181082T1 (hr) 2018-09-07
US20170014407A1 (en) 2017-01-19

Similar Documents

Publication Publication Date Title
CL2018002012A1 (es) Derivados de maitansinoide, conjugados de los mismos y métodos de uso.
CL2015002472A1 (es) Como inhibidores de mutant idh-yl-oxazolidin-2-onas 3-pirimidin-4.
CL2018000978A1 (es) Macrociclos peptídicos contra acinetobacter baumannii
CL2015002891A1 (es) Deaza-purinonas macrocíclicas para el tratamiento de infecciones virales.
CL2016002735A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
CL2016002151A1 (es) Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
CL2016001231A1 (es) Compuestos de inhibidor de autotaxina
CL2014002873A1 (es) Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
CL2015002194A1 (es) Inhbidores de erk y sus usos
MX2017012380A (es) Derivados de maitansinoide, conjugados de los mismos, y metodos de uso.
MX378273B (es) Compuestos activos hacia bromodominios.
MX2020011104A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
CL2014001793A1 (es) Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
CL2016001609A1 (es) Composiciones farmacéuticas que comprenden azd9291.
BR112016015706A2 (pt) composto, uso do mesmo e composição farmacêutica
MX2016014247A (es) Conjugados de anticuerpo-farmaco anti-proteina tirosina quinasa 7 (anti-ptk7).
CL2016003422A1 (es) Inhibidores de demetilasa-1 específico de lisina
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
CL2012003415A1 (es) Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer .
CL2016002169A1 (es) Inhibidores de diacilglicerol aciltransferasa 2 para uso en el tratamiento de trastornos metabólicos y relacionados.
CL2016003423A1 (es) Inhibidores de demetilasa-1 específico de lisina
CL2015002897A1 (es) Inhibidores de bace1
EA201791454A1 (ru) Лекарственные формы для трансдермального введения